Companies in the global proliferative diabetic retinopathy market are
employing strategic initiatives that include product development,
geographical expansion, acquisitions, and mergers. These strategies
are likely to aid the market players in advancing their businesses
and increasing their market footprint. For example, ThromboGenics
initiated partnership with Novartis (Alcon) for assisting in
commercialization and marketing activities of JETREA beyond the U.S.
Request for Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=40637
On similar lines, Alimera initiated sales of ILLUVEN in the U.K. and
Germany, in a bid to foray the European market. The initiative was
primarily aimed at tapping new markets and boosting revenue
generation of the company. A new report of Transparency Market
Research has profiles key players making notable contribution to
expansion of the global market for proliferative diabetic
retinopathy, which include Pfizer, Inc., Genentech, Inc. (Roche
Holdings), Merck KGaA, Allergan Plc, Santen Pharmaceutical Co., Ltd.,
Cipla, Ltd., Regeneron Pharmaceuticals, Inc., Valeant Pharmaceuticals
International, Inc., Intas Pharmaceuticals Limited, and Novartis AG.
Demand for Proliferative Diabetic Retinopathy Treatment Drugs to
Remain Robust
According to World Health Organization, number of people affected
with diabetes has exceeded 400 Mn, in case of adults, in 2014.
Additionally, global prevalence of diabetes doubled, rising at over
8% in adult population. The Department of Assistive and
Rehabilitative Services (DARS) has reported that nearly 80% of the
diabetic population was affected from diabetic retinopathy in 2013,
with a notable portion of this percentile estimated to acquire the
proliferative condition. These numbers are further poised to witness
a rise in the years to come, driven by unhealthy consumption patterns
and comfort-driven lifestyles of consumers worldwide. This will
further have a robust impact on demand for treatment drugs apropos to
proliferative diabetic retinopathy in the foreseeable future.
Request Report Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=40637
The report estimates the market to record a splendid rise over the
forecast period 2017 to 2026. Nearly US$ 1,000 Mn worth of drugs for
treatment of proliferative diabetic retinopathy are anticipated to be
sold worldwide by 2026-end. Considered as a serious sight threatening
ailment on account of long-term exposure to diabetes, diabetic
retinopathy results into progressive retinal damage and affects
retinal circulatory system. Extremity of the disease, which may lead
to proliferative condition, determines the selection of effective
therapeutic measure, thereby entailing requirement for intraocular
injections, laser surgery, vitrectomy, or anti-VEGF drug
prescriptions.
North America to Stay at Forefront of Global Proliferative
Diabetic Retinopathy Market
In terms of revenues, North America is likely to remain at the
forefront of the global proliferative diabetic retinopathy, driven by
supportive reimbursement policies offered by the government coupled
with greater prevalence of diabetes in the region. Additionally,
robust penetration of management drugs such as anti-VEGF drugs viz.
Lucentis, Avastin, and Eylea, has further supported revenue
generation from treatment of this disease in North America. Europe
and Asia-Pacific excluding Japan are also likely to endure as
significant revenue contributors to the global proliferative diabetic
retinopathy market.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=40637
Anti-VEGF drugs are likely to remain preferred among various drug
class utilized for treatment of proliferative diabetic retinopathy
across the globe. Revenues from sales of anti-VEGF drugs are poised
to reach approximately US$ 700 Mn by 2026-end. Although
corticosteroids’ sales are expected to record an impressive
expansion in the market, revenues from this drug class will continue
to be sluggish.
About Us
Transparency Market Research is a next-generation market intelligence
provider, offering fact-based solutions to business leaders,
consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow,
evolve, and mature. Our real-time data collection methods along with
ability to track more than one million high growth niche products are
aligned with your aims. The detailed and proprietary statistical
models used by our analysts offer insights for making right decision
in the shortest span of time. For organizations that require specific
but comprehensive information we offer customized solutions through
adhoc reports. These requests are delivered with the perfect
combination of right sense of fact-oriented problem solving
methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems
with right methodology of research is the key to help enterprises
reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment